SU2C-SARC032 : A Phase II Randomized Controlled Trial of Neoadjuvant Pembrolizumab With Radiotherapy and Adjuvant Pembrolizumab in Patients With High-Risk, Localized Soft Tissue Sarcoma of the Extremity

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Multiple<Br/>Treatment TypesTypeMultiple
Treatment Types

TwoPhase Two

12+Age Over 12

Advanced CancersCancer LocationMulti-Cancer
Trial

Multiple treatment types,Radiotherapy,Surgical,Systemic therapy | Sarcoma,Skin,Urinary systemBasal cell carcinoma,Cutaneous Squamous Cell Carcinoma (CSCC),Liposarcoma,Prostate,Sarcoma,Soft Tissue Sarcoma,Squamous cell carcinoma

Trial Overview Read MoreRead more

This Phase II trial is trying to determine whether using immunotherapy and radiotherapy for the treatment of localised, high-risk soft tissue sarcoma is more effective than giving radiotherapy alone.
 

This trial is treating patients with soft tissue sarcoma.

This is a systemic therapy, radiotherapy and surgical.

You may be able to join this trial if:

  • Your cancer has not spread to other parts of the body.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have been diagnosed with a prior or secondary type of cancer.
  • You have had certain treatments, surgical procedures or drugs.
  • You have previously been treated (or are currently being treated) on a clinical trial.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A Phase II Randomized Controlled Trial of Neoadjuvant Pembrolizumab With Radiotherapy and Adjuvant Pembrolizumab in Patients With High-Risk, Localized Soft Tissue Sarcoma of the Extremity

Cooperative Group

Sarcoma Alliance for Research through Collaboration

Summary

Participants will be randomised into an experimental or standard of care arm of the study. In the experimental arm, participants will receive neoadjuvant pembrolizumab with concurrent radiotherapy, followed by surgical resection and adjuvant pembrolizumab. In this study, standard of care will include neoadjuvant radiotherapy followed by surgical resection. This trial is recruiting patients with undifferentiated pleomorphic sarcoma or dedifferentiated/pleomorphic Liposarcoma of the extremity. Patients with non-melanomatous skin cancer, in situ carcinoma, or low-risk prostate cancer will also be considered for enrolment in this study.

Recruiting Hospitals Read MoreRead more

PCCTU (Parkville Cancer Clinical Trials Unit) *
Parkville
Ms Marian Lieschke
marian.lieschke@petermac.org
03 8559 7140

St Vincent's Hospital, Medical and Radiation Oncology
Fitzroy
Ms Nadia Ranieri
oncology.research@svha.org.au
03 9288 3167

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next